Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Trea...
Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors
About this item
Full title
Author / Creator
Occhipinti, Mario , Brambilla, Marta , Galli, Giulia , Manglaviti, Sara , Giammaruco, Maristella , Prelaj, Arsela , Ferrara, Roberto , De Toma, Alessandro , Proto, Claudia , Beninato, Teresa , Zattarin, Emma , Lo Russo, Giuseppe , Gelibter, Alain Jonathan , Simmaco, Maurizio , Preissner, Robert , Garassino, Marina Chiara , De Braud, Filippo and Marchetti, Paolo
Publisher
Basel: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Basel: MDPI AG
Subjects
More information
Scope and Contents
Contents
(1) Background. The onset of a drug–drug interaction (DDI) may affect treatment efficacy and toxicity of advanced non-small-cell lung cancer (aNSCLC) patients during epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) use. Here we present the use of Drug-PIN® (Personalized Interactions Network) software to detect DDIs in aNSCLC...
Alternative Titles
Full title
Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors
Authors, Artists and Contributors
Author / Creator
Brambilla, Marta
Galli, Giulia
Manglaviti, Sara
Giammaruco, Maristella
Prelaj, Arsela
Ferrara, Roberto
De Toma, Alessandro
Proto, Claudia
Beninato, Teresa
Zattarin, Emma
Lo Russo, Giuseppe
Gelibter, Alain Jonathan
Simmaco, Maurizio
Preissner, Robert
Garassino, Marina Chiara
De Braud, Filippo
Marchetti, Paolo
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8157378
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8157378
Other Identifiers
ISSN
2075-4426
E-ISSN
2075-4426
DOI
10.3390/jpm11050424
